Updated:
Sarsia
Sarsia was founded in 2005 as a Nordic early-stage venture firm anchored in Bergen, Norway. Managing Partner Sveinung Hole rejoined the firm after leading...
Sarsia
Sarsia was founded in 2005 as a Nordic early-stage venture firm anchored in Bergen, Norway. Managing Partner Sveinung Hole rejoined the firm after leading Norway’s largest research-funding foundations, setting a tone that blends public-sector rigor with private-venture discipline. The firm does not disclose an originating family wealth source, operating instead as a traditional VC raising closed-end funds from institutional and private limited partners. Sarsia runs a concentrated strategy across life sciences and technology-energy-sustainability, investing seed and early-stage tickets into companies spun out of Nordic research environments. The current portfolio of 24 companies confirms active positions in clinical-stage biotechs such as Calluna Pharma, APIM Therapeutics, and Coegin Pharma, alongside industrial-tech and climate-named bets including Heimdall Power (grid monitoring via IoT), Cetasol (AI-driven vessel efficiency), and WindSim (wind-farm design software). A meaningful portion of the life-sciences book addresses unmet medical needs in oncology, immunology, and infectious disease, while the sustainability side spans the energy transition from EV charging infrastructure (Enua, Chargitect) to ocean data (Offshore Sensing) and maritime logistics (Keelspot). Geographically the firm concentrates deal flow from Norway and broader Scandinavia, with select European exposure via Swedish assets like Cetasol and portfolio linkages to markets in Germany, France, and the UK. Sarsia has raised three funds to date, amassing a reported total of NOK 1.3 billion in commitments — the composition points to a disciplined fund-cycle cadence rather than a permanent-capital structure. The partnership lists 14 professionals on its website, a number heavily weighted toward domain-deep operators: PhDs in microbiology, pharmacology, oceanography, and applied physics sit alongside AFA- and CEFA-qualified finance partners. In May 2026, portfolio company SonoClear completed the final patient procedure in its ultrasound-study enrollment, demonstrating the firm’s continued support for capital-intensive clinical-stage programs deep into their trials. Sarsia’s structural edge lies in a partnership model that embeds scientific practitioners directly into IC-level roles rather than relegating technical diligence to external advisors. Partners such as Øivind Enger (molecular biology) and Farzad Abdi-Dezfuli (pharmacology) personally lead life-science deals, while industrial-tech investments are steered by a team of engineers who hold CEFA financial-analyst credentials. This dual-literacy architecture reduces the principal–agent gap that plagues generalist venture firms dabbling in deep-tech, making Sarsia’s Nordic research-to-seed pipeline unusually self-contained.
General information
Firm type
Private Equity
Year founded
2005
AUM
Undisclosed
Location
Region
Europe
Country
Norway
City
Bergen
Corporate office
Bergen, Norway
Principals
Sveinung Hole
Managing Partner
Marit Wick
Partner and CFO
Øivind Enger
Partner, Life Science
Jon Trygve Berg
Partner Technology, Energy and Sustainability
Farzad Abdi-Dezfuli
Partner Life Sciences
Hilde Holdhus
Partner Technology, Energy and Sustainability
Jon-Kåre Hansen
Partner Technology, Energy and Sustainability
Henrik Solberg-Johansen
Partner Technology, Energy and Sustainability
Erlend Skagseth
Senior Partner
Maija Slaidiņa
Investment Manager, Life Science
Sector focus
Frequently asked questions
Who runs investment decisions at Sarsia?
Sveinung Hole serves as Managing Partner and anchors the investment committee alongside a sector-specialist partnership. Life-science decisions are led by partners Øivind Enger and Farzad Abdi-Dezfuli, both PhD-level scientists, while technology and sustainability deals are managed by partners Jon Trygve Berg, Hilde Holdhus, Jon-Kåre Hansen, and Henrik Solberg-Johansen — each pairing engineering or operational backgrounds with formal financial-analyst credentials.
How does Sarsia source its deal flow?
Sarsia sources predominantly from Nordic research universities and affiliated technology-transfer offices. The team’s academic background and its physical base in Bergen create direct pathways into Norwegian innovation clusters in marine, energy, and life sciences. Several partners previously managed research-commercialization units, giving them early visibility into spin-out opportunities before they register with pan-European venture platforms.
Does Sarsia operate as a family office or a traditional venture firm?
Sarsia operates as a traditional venture capital firm raising closed-end funds from external limited partners, not as a single-family office. It has managed three successive funds totaling NOK 1.3 billion and is structured as an asset manager, not a permanent-capital vehicle tied to a specific family’s wealth.
What investment stages does Sarsia target?
The firm concentrates on seed and early-stage equity rounds, with the capacity to follow on through clinical- or commercial-milestone financings. Its portfolio includes pre-revenue life-science companies progressing from Phase 1 through registration trials, as well as pre-commercial industrial-tech startups that have validated prototypes or first pilot customers.
Does Sarsia lead rounds or co-invest alongside other VCs?
Sarsia employs a co-investment approach, often leading or co-leading seed rounds into Nordic startups and syndicating follow-on capital with domestic and international venture firms. Its website emphasizes connecting founders to broader venture capital networks, and several portfolio companies — such as Nykode and BerGenBio — have progressed to public listings or attracted later-stage crossover investors.
Which sectors does Sarsia explicitly avoid?
Sarsia’s two stated investment areas — life sciences and technology, energy and sustainability — exclude pure-play software-as-a-service, consumer internet, and financial technology. The firm’s portfolio and partner biographies confirm no meaningful allocations to ad-tech, social media, or developer-tool startups unconnected to a physical-science or engineering advance.
Where does Sarsia’s capital come from, and how is it governed?
The firm’s capital comes from institutional and private limited partners through three commingled venture funds; it has not disclosed a single-family or endowment anchor. Governance is carried out by the partnership, with Olav Skjervheim serving as compliance officer overseeing regulatory adherence under Norwegian fund-management rules, a structure more aligned with a regulated asset manager than an unconstrained family office.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: